Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactobacillus reuteri CCFM1134 for preventing and relieving ulcerative colitis and application thereof

A technology for Lactobacillus reuteri and ulcerative colitis, applied in the field of functional microorganisms, can solve problems such as many side effects and limited therapeutic effect, and achieve the effect of reducing MPO activity, wide application prospects, and improving colonic mucosal damage

Active Publication Date: 2021-04-13
JIANGNAN UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These three drugs have limited therapeutic effects on UC and have many side effects. Therefore, it is of great significance to develop new measures to effectively prevent or adjuvantly treat UC to reduce the occurrence of the disease and enhance the therapeutic effect of the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus reuteri CCFM1134 for preventing and relieving ulcerative colitis and application thereof
  • Lactobacillus reuteri CCFM1134 for preventing and relieving ulcerative colitis and application thereof
  • Lactobacillus reuteri CCFM1134 for preventing and relieving ulcerative colitis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1: Lactobacillus reuteri CCFM1134 has good tolerance to simulated gastrointestinal fluid

[0055] The cryopreserved Lactobacillus reuteri CCFM1134 was inoculated in mMRS medium (MRS medium + 0.05% cysteine ​​hydrochloride), anaerobically cultured at 37°C for 48 hours, and subcultured in mMRS medium for 2~ After 3 times, take 1 mL of the culture solution of Lactobacillus reuteri CCFM1134, mix it with 9.0 mL of pH 2.5 artificial simulated gastric juice (mMRS medium containing 1% pepsin, pH=2.5), and culture it anaerobically at 37°C. Samples were taken at 0h, 0.5h, 1h, 2h, and 3h, and the mMRS agar medium was poured to culture the plate colonies, and the number of viable bacteria was determined and the survival rate was calculated.

[0056] Take 1 mL of the culture solution of Lactobacillus reuteri CCFM1134 and add it to 9 mL of artificial simulated intestinal fluid (mMRS medium containing 0.3% ox bile salt, 1% trypsin, pH=8.0), and culture it anaerobically at 37°C...

Embodiment 2

[0062] Example 2: Lactobacillus reuteri CCFM1134 has no toxic side effects on C57BL / 6J mice

[0063] Suspend Lactobacillus reuteri CCFM1134 in 3g / 100mL sucrose solution to make a concentration of 5.0×10 9 CFU / mL bacterial suspension. Take 6 healthy male C57BL / 6J mice with a body weight of about 14-16g. After adapting to the environment for a week, they are given the bacterial suspension of this concentration by gavage once a day (0.2mL per gavage), observed for a week, and recorded the death and body weight. .

[0064] The results of these tests are listed in Table 3. These results indicated that feeding concentrations of 5.0×10 9 CFU / mL of Lactobacillus reuteri CCFM1134 had no significant impact on mice, no significant change in body weight, and no death. The appearance of the mice had no obvious pathological symptoms.

[0065] Table 3 Changes in body weight and death of mice

[0066] time (days) 1 2 3 4 5 6 7 weight(g) 19.73±0.32 20.12±0.41 20....

Embodiment 3

[0068] Example 3: Effect of Lactobacillus reuteri CCFM1134 on disease symptoms in UC mice

[0069] Take 30 healthy male C57BL / 6J mice weighing 14-16g, adapt to the environment for 1 week, 6 mice in each group, and randomly divide them into 5 groups: blank group, model group, drug group, Lactobacillus reuteri CCFM1134 intervention group (CCFM1134), Lactobacillus reuteri FCQHC8L6 control group (FCQHC8L6). The dose of intragastric bacterial suspension was 5.0×10 9 CFU / mL, resuspended in 3g / 100mL sucrose solution, 0.2mL per gavage. In the 5th week, dextran sulphate sodium (DSS) was added to the drinking water to make the final concentration of dextran sulphate sodium 2.5g / 100mL for 7 days to induce colitis in mice. The grouping and treatment methods of experimental animals are shown in Table 4:

[0070] Table 4 Animal grouping and treatment methods

[0071]

[0072] In the fifth week, that is, during the modeling period (ie, during DSS treatment), the body weight of the mic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses lactobacillus reuteri CCFM1134 for preventing and relieving ulcerative colitis and application thereof, and belongs to the technical field of functional microorganisms. The lactobacillus reuteri CCFM1134 can tolerate the human gastrointestinal environment, significantly reduce weight loss during the ulcerative colitis, improve fecal traits and hematochezia, improve colon mucosal injury, reduce MPO activity, reduce the content of pro-inflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in colon, up-regulate the transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, up-regulate transcription levels of antibacterial peptides Reg3g and Reg3b, up-regulate the transcription level of mucoprotein MUC2 in colons, and improve the diversity of intestinal flora.

Description

technical field [0001] The present invention relates to Lactobacillus reuteri CCFM1134 for preventing and alleviating ulcerative colitis and its application, in particular to the application of Lactobacillus reuteri CCFM1134 in the preparation of functional bacterial agents, food and / or medicine, which belongs to functional microbial technology field. Background technique [0002] Ulcerative colitis (UC) is a recurrent gastrointestinal disease, the main clinical manifestations of chronic or subacute diarrhea, mucus pus and blood in the stool and abdominal pain. UC is a continuous inflammation of colonic mucosa and submucosa, and the disease usually starts from the rectum and spreads to the whole colon. The lesions are mostly located in the sigmoid colon and rectum, and can also extend to the descending colon, or even the entire colon. Intestinal tight junctions in lesions are damaged, transmembrane proteins Claudins, Occludin, JAM and intracellular proteins ZO family (incl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20A61K35/747A61P1/04A23C9/123A23C13/16A23C19/06A23L2/38A23L2/84A23L11/50A23L29/00A23L33/135C12R1/225
CPCA61K35/747A61P1/04A23C9/1234A23C13/16A23C19/062A23L2/382A23L2/84A23L29/065A23L33/135A23V2002/00A23V2400/173A23V2200/3204A23V2250/5114A23V2250/636
Inventor 王刚郑雨星王琳琳赵建新张灏陈卫
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com